← Browse by Condition
Medical Condition

multiple myeloma

Total Trials
54
Recruiting Now
54
Trial Phases
Phase 2, Phase 1, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for multiple myeloma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — multiple myeloma Clinical Trials

How many clinical trials are currently recruiting for multiple myeloma?
ClinicalMetric currently tracks 54 actively recruiting clinical trials for multiple myeloma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 54. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for multiple myeloma?
multiple myeloma research spans Phase 1 (17 trials), Phase 2 (23 trials), Phase 3 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a multiple myeloma clinical trial?
Eligibility criteria for multiple myeloma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
17
Phase 2
23
Phase 3
5
Top Sponsors
Institute of Hematology & Blood Diseases Hospital, China 5 trials
Zhujiang Hospital 2 trials
Washington University School of Medicine 2 trials
Shanghai Zhongshan Hospital 2 trials
Memorial Sloan Kettering Cancer Center 2 trials

Recruiting Clinical Trials

NCT06539832
Recruiting
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
Enrollment
300 pts
Location
China
Sponsor
Zhujiang Hospital
View Trial →
NCT06103838 Phase 2
Recruiting
18F-Fluciclovine PET/CT in Multiple Myeloma
Enrollment
60 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT06297226 Phase 2
Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Enrollment
230 pts
Location
United States, Austr...
Sponsor
Juno Therapeutics, Inc., a Bri...
View Trial →
NCT06799026 Phase 1
Recruiting
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Enrollment
25 pts
Location
United States
Sponsor
David Avigan
View Trial →
NCT07205523
Recruiting
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Enrollment
1,000 pts
Location
China
Sponsor
Yigeng Cao,MD,PhD
View Trial →
NCT06505369 Phase 2
Recruiting
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Enrollment
50 pts
Location
Denmark, Estonia, No...
Sponsor
North Estonia Medical Centre
View Trial →
NCT06910124 Phase 2
Recruiting
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Enrollment
32 pts
Location
United States
Sponsor
Dickran Kazandjian, MD
View Trial →
NCT05231629 Phase 2
Recruiting
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
Enrollment
300 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT06236373
Recruiting
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
Enrollment
45 pts
Location
Italy
Sponsor
University of Modena and Reggi...
View Trial →
NCT06999031 EARLY_Phase 1
Recruiting
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment
12 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06572605 Phase 1, Phase 2
Recruiting
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
Enrollment
20 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →
NCT05706766
Recruiting
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Enrollment
30 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT06932562 Phase 3
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Enrollment
1,000 pts
Location
Australia, Austria, ...
Sponsor
European Myeloma Network B.V.
View Trial →
NCT06350994
Recruiting
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
Enrollment
60 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT06338150
Recruiting
Precision Medicine Study
Enrollment
100 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo...
View Trial →
NCT06216158 Phase 3
Recruiting
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
Enrollment
411 pts
Location
Austria, Germany
Sponsor
University of Heidelberg Medic...
View Trial →
NCT07226934
Recruiting
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Enrollment
40 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT06690593
Recruiting
Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
Enrollment
2,990 pts
Location
China
Sponsor
Zhujiang Hospital
View Trial →
NCT06252792
Recruiting
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Enrollment
50 pts
Location
China
Sponsor
FengYan Jin
View Trial →
NCT06515249
Recruiting
Integrative Therapies in Multiple Myeloma
Enrollment
300 pts
Location
Israel
Sponsor
Bnai Zion Medical Center
View Trial →
NCT05965115
Recruiting
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
Enrollment
10,000 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →
NCT06793449 Phase 2
Recruiting
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
Enrollment
80 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT05853965 Phase 1, Phase 2
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
Enrollment
45 pts
Location
Germany
Sponsor
Universitätsklinikum Hamburg-E...
View Trial →
NCT05879757
Recruiting
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Enrollment
75 pts
Location
Argentina, Czechia, ...
Sponsor
Takeda
View Trial →
NCT07169500 Phase 1, Phase 2
Recruiting
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Enrollment
50 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT03308474
Recruiting
Myeloma Registry Platform (MYRIAM)
Enrollment
2,200 pts
Location
Germany
Sponsor
iOMEDICO AG
View Trial →
NCT07319897 Phase 2, Phase 3
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
Enrollment
300 pts
Location
China
Sponsor
Peking University First Hospit...
View Trial →
NCT05632380 Phase 1, Phase 2
Recruiting
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Enrollment
20 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT05299424 Phase 1, Phase 2
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment
48 pts
Location
China
Sponsor
Keymed Biosciences Co.Ltd
View Trial →
NCT06644118 Phase 1
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment
58 pts
Location
China
Sponsor
Zhejiang University
View Trial →
NCT05645510
Recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Enrollment
75 pts
Location
Canada
Sponsor
University of Alberta
View Trial →
NCT07249073 EARLY_Phase 1
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Enrollment
9 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT04513639 Phase 2, Phase 3
Recruiting
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Enrollment
176 pts
Location
Norway
Sponsor
Oslo University Hospital
View Trial →
NCT03717844
Recruiting
Registry for Adults With Plasma Cell Disorders (PCD's)
Enrollment
2,000 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
View Trial →
NCT05972135 Phase 2
Recruiting
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Enrollment
100 pts
Location
United States
Sponsor
SCRI Development Innovations, ...
View Trial →
NCT06679101 Phase 3
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Enrollment
520 pts
Location
United States, Argen...
Sponsor
GlaxoSmithKline
View Trial →
NCT07638683 Phase 2
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Enrollment
30 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →
NCT05521802 Phase 1, Phase 2
Recruiting
A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment
92 pts
Location
China
Sponsor
Shanghai AbelZeta Ltd.
View Trial →
NCT07489534 Phase 2
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Enrollment
25 pts
Location
China
Sponsor
Daihong Liu
View Trial →
NCT04483206 Phase 1
Recruiting
Personalized Autologous Transplant for Multiple Myeloma
Enrollment
90 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT05789303 Phase 2
Recruiting
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Enrollment
83 pts
Location
United States
Sponsor
University of Chicago
View Trial →
NCT06976476 Phase 2
Recruiting
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Enrollment
100 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT07188090 Phase 2
Recruiting
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Enrollment
100 pts
Location
United States
Sponsor
Thomas Jefferson University
View Trial →
NCT05651932 Phase 1
Recruiting
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Enrollment
165 pts
Location
United States, Canad...
Sponsor
K36 Therapeutics, Inc.
View Trial →
NCT04795882 Phase 1
Recruiting
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Enrollment
27 pts
Location
United Kingdom
Sponsor
University College, London
View Trial →
NCT06659276
Recruiting
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
Enrollment
83 pts
Location
Italy
Sponsor
IRCCS Azienda Ospedaliero-Univ...
View Trial →
NCT05968417
Recruiting
Myeloma Novel Drug Discovery Ver 1.2
Enrollment
250 pts
Location
United Kingdom
Sponsor
Institute of Cancer Research, ...
View Trial →
NCT07099391 Phase 1, Phase 2
Recruiting
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Enrollment
65 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT03375619
Recruiting
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Enrollment
500 pts
Location
United States
Sponsor
Medical College of Wisconsin
View Trial →
NCT04645199
Recruiting
National Longitudinal Cohort of Hematological Diseases
Enrollment
2,300 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT06083207 Phase 1, Phase 2
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment
116 pts
Location
Australia, China
Sponsor
Innovent Biologics (Suzhou) Co...
View Trial →
NCT06536413 Phase 1, Phase 2
Recruiting
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
Enrollment
42 pts
Location
United States
Sponsor
The Methodist Hospital Researc...
View Trial →
NCT07200089 Phase 1
Recruiting
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Enrollment
52 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT02869555
Recruiting
Institut Paoli Calmettes Multiple Myeloma Database
Enrollment
5,000 pts
Location
France
Sponsor
Institut Paoli-Calmettes
View Trial →

Related Conditions

lymphoma (4) m protein (2) relapse multiple myeloma (2) hemophilia (2) myelodysplastic syndrome (2) mds (2) leukemia (2) aplastic anemia (2) bone marrow transplantation (2) myeloma multiple (2) cancer (2) breast cancer (2)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology